Benzinga · Aug 12, 2026
Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday?
Rhythm Pharma shares rise after U.K. expands Imcivree authorization for acquired hypothalamic obesity in adults and children 4 and older.
RY
NASDAQ · RYTM
Rhythm Pharmaceuticals, Inc.
Healthcare · Biotechnology
$108.92
Up+$1.08 (+0.99%)
Updated Aug 22, 2026, 1:10 AM
SID Score
5.6/10
Composite research score
Smart Money
62/100
Neutral
- Market cap
- 7.84B
- P/E ratio
- -39.32
- Dividend yield
- 0.00%
- 52-week range
- $74.50 – $122.20
- Volume
- 568.58K
- Avg. volume
- 655.95K
Price performance
RYTM price history
1M range · 21 trading sessions · Daily adjusted prices
RYTM closed at $110.00 after 21 trading sessions, up 7.74% for the selected period.
- Last close
- $110.00
- Period change
- +7.74%
- Period low
- $99.25
- Period high
- $117.60
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $109.38 | $112.59 | $106.58 | $110.00 | 523.14K |
| Aug 20, 2026 | $114.51 | $114.605 | $108.7267 | $108.92 | 568.58K |
| Aug 19, 2026 | $118.31 | $118.31 | $115.26 | $115.73 | 669.9K |
| Aug 18, 2026 | $115.25 | $117.16 | $114.325 | $115.25 | 447.06K |
| Aug 17, 2026 | $115.40 | $117.18 | $114.44 | $115.44 | 412.05K |
| Aug 14, 2026 | $115.22 | $117.3337 | $113.66 | $115.48 | 334.88K |
| Aug 13, 2026 | $118.18 | $119.75 | $114.00 | $116.02 | 759.78K |
| Aug 12, 2026 | $111.58 | $118.50 | $111.42 | $117.60 | 574.31K |
| Aug 11, 2026 | $113.17 | $117.485 | $112.51 | $112.845 | 728.86K |
| Aug 10, 2026 | $115.57 | $116.89 | $113.6725 | $115.48 | 738.55K |
| Aug 7, 2026 | $113.17 | $116.18 | $111.6901 | $115.63 | 672.76K |
| Aug 6, 2026 | $110.03 | $112.30 | $108.49 | $112.10 | 944.32K |
| Aug 5, 2026 | $110.83 | $111.10 | $105.13 | $110.71 | 1.09M |
| Aug 4, 2026 | $100.68 | $108.65 | $97.565 | $105.78 | 1.64M |
| Aug 3, 2026 | $100.395 | $103.49 | $97.99 | $102.78 | 964.32K |
| Jul 31, 2026 | $105.74 | $106.87 | $98.435 | $99.25 | 471.7K |
| Jul 30, 2026 | $105.48 | $106.90 | $102.58 | $105.74 | 534.59K |
| Jul 29, 2026 | $107.62 | $108.40 | $105.86 | $106.53 | 502.19K |
| Jul 28, 2026 | $107.13 | $110.99 | $106.02 | $108.04 | 1.15M |
| Jul 27, 2026 | $104.64 | $109.53 | $102.75 | $106.13 | 727.72K |
| Jul 24, 2026 | $103.92 | $104.87 | $101.49 | $102.10 | 467.13K |
Latest RYTM news
The latest Smart Investors Daily articles mentioning RYTM.
Stock researchCompany · Overview
RYTM research
Overview
Company profile and research snapshot.
Company profile
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $130.20
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | JP Morgan | Overweight | — |
| Aug 5, 2026 | Citizens | Market Outperform | — |
| Aug 5, 2026 | RBC Capital | Outperform | — |
| Aug 5, 2026 | Citigroup | Buy | — |
| Jul 27, 2026 | JP Morgan | Overweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 7, 2026
JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146
JP Morgan analyst Priyanka Grover maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price target from $145 to $146.
Benzinga · Aug 5, 2026
Citigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143
Citigroup analyst Samantha Semenkow maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $142 to $143.
Benzinga · Aug 5, 2026
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155
RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Outperform and raises the price target from $141 to $155.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
